Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects
about
Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients.Anthracycline cardiotoxicity.Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patientsMyocardial protective effect of tezosentan, an endothelin receptor antagonist, for ischemia-reperfusion injury in experimental heart failure models.Timely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist.Cardiotoxicity of childhood cancer treatment: update and current knowledge on long-term follow-up.Alternative Biomarkers for Combined Biology.Biomarkers for monitoring chemotherapy-induced cardiotoxicity.The Cardiac Markers and Oxidative Stress Parameters in Advanced Non-Small Cell Lung Cancer Patients Receiving Cisplatin-Based ChemotherapyPlasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer.Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction.
P2860
Q27027354-03221948-0E31-48B8-9223-67B466474FB1Q34659375-7597D268-083E-496D-9379-C3B0DE61D20CQ35623306-FE66ADFD-6F6F-478E-918F-50E0E99F1598Q36624983-5ABFBEA2-18A3-4ADF-8925-681D6E41C225Q36644505-D3CDDC5B-EEDB-42A0-8613-5D715D03AA01Q37364486-A3F924CB-ED5E-4634-9E11-C43C7F6229FDQ37926954-DD5EDEC7-F83B-491F-9A3E-D9BBE0D2B9D9Q38021523-588421C0-9CE5-4D1E-8DED-8E90E6851F8BQ38747992-2585BC88-80AC-4B9D-A3D0-A089109F5430Q39053477-275CD135-47F0-445F-8B51-9B3FD15E7E40Q42378419-3A117262-90DC-4C15-B756-150421F97E20Q43683844-32FDCD7D-70B9-433B-B48E-DB2B8B7D4723Q45218584-42EAC427-5FD3-4B81-BB9A-47C7D9BC483D
P2860
Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects
description
1992 nî lūn-bûn
@nan
1992 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի մարտին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects
@ast
Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects
@en
Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects
@nl
type
label
Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects
@ast
Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects
@en
Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects
@nl
prefLabel
Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects
@ast
Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects
@en
Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects
@nl
P2093
P1433
P1476
Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects
@en
P2093
P304
P356
10.1002/1097-0142(19920315)69:6<1492::AID-CNCR2820690630>3.0.CO;2-3
P407
P577
1992-03-15T00:00:00Z